Abstract
Aseptic meningitis and acute parotitis have been observed after mumps vaccination. Mumps outbreaks have been reported in Japan because of low vaccine coverage, and molecular differentiation is required to determine whether these cases are vaccine associated. RT-nested PCR was performed in the small hydrophobic gene region, and viruses were differentiated by restriction fragment length polymorphism assay. A total of 584 nucleotides were amplified. The PCR product of the Hoshino strain was cut into two fragments (313 and 271 nucleotides) by MfeI; that of the Torii strain was digested with EcoT22I, resulting in 332- and 252-nucleotide fragments. Both strains were genotype B and had an XbaI site, resulting in two fragments: 299 and 285 nucleotides. Current circulating wild types were cut only by XbaI or MfeI. However, the MfeI site of the wild types was different from that of the Hoshino strain, resulting in 451- and 133-nucleotide fragments. Using three restriction enzymes, two mumps vaccine strains were distinguished from wild types, and this separation was applied to the identification of vaccine-related adverse events.
Similar content being viewed by others
References
Kimura M, Kuno-Sakai H, Yamazaki S. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn. 1996;38:205–11.
Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles–mumps–rubella vaccine in Japan. Lancet. 1995;346:701–2.
Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007;25:2742–7.
Jin L, Rima B, Brown D, Örvell C, Técle T, Afzal M, et al. Proposal for genetic characterization of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol. 2005;150:1903–9.
WHO. Mumps virus nomenclature update: 2012. A report based on the WHO mumps nomenclature update meeting, Geneva, 22 September 2011. Wkly Epidemiol Rec. 2012;87:217–24.
Sasaki K, Higashihara M, Inoue K, Igarashi Y. Studies on the development of a live attenuated mumps virus vaccine. Kitasato Arch Exp Med. 1976;49:43–52.
Hoshino M, Nishimitsu M, Ichimori Y, Oka Y, Kouno R, Yamashita K, et al. Development of live attenuated mumps Torii vaccine strain: development and biological characteristics. Clin Virol. 1981;9:323–30. (in Japanese).
Kashiwagi Y, Takami T, Mori T, Nakayama T. Sequence analysis of F, SH, and HN genes among mumps virus strains in Japan. Arch Virol. 1999;144:593–9.
Takahashi M, Nakayama T, Kashiwagi Y, Takami T, Sonoda S, Yamanaka T, et al. Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating. J Med Virol. 1996;62:278–85.
Inou Y, Nakayama T, Yoshida N, Uejima H, Yuri K, Kamada M, et al. Molecular epidemiology of mumps virus in Japan and proposal of two new genotypes. J Med Virol. 2004;73:97–104.
Otto W, Mankertz A, Santibanez S, Saygilli H, Wenzel J, Jilg E, et al. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Eur Surveill 2010;15(50):19748
Kashiwagi Y, Kawashima H, Takekuma K, Hoshika A, Mori T, Nakayama T. Detection of mumps virus genome directly from clinical samples and a simple method for genetic differentiation of the Hoshino vaccine strain from wild strains of mumps virus. J Med Virol. 1997;52:195–9.
Yoshida N, Fujino M, Ota Y, Notomi T, Nakayama T. Simple differentiation of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP). Vaccine. 2007;25:1281–6.
CDC. Mumps epidemic—United Kingdom, 2004–2005. MMWR. 2006;55:173–5.
CDC. Mumps outbreak at a summer camp: New York, 2005. MMWR. 2006;55:175–7.
Barskey AE, Glasser J, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine. 2009;27:6186–95.
Rubin SA, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, et al. Antibody induced by immunization with Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508–15.
Rubin SA, Link MA, Sauder CJ, Zhang C, Ngo L, Rima BK, et al. Mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615–20.
Atrasheuskaya AV, Blatun EM, Kulak MV, Atrasheuskaya A, Karpov IA, Rubin S. Investigation of mumps vaccine failures in Minsk, Belarus, 2001–2003. Vaccine. 2007;25:4651–8.
Takami T, Kawashima H, Takei Y, Miyajima T, Mori T, Nakayama T, et al. Usefulness of nested PCR and sequence analysis in a nosocomial outbreak of neonatal enterovirus infection. J Clin Virol. 1998;11:67–75.
Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994–2004. Vaccine. 2007;25:570–6.
Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, editors. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008. p. 435–65.
Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17:661–7.
Hashimoto H, Fujioka M, Kinumaki H, Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28:173–5.
Conflict of interest
The author has a conflict of interest. T.N. has received a research fund for the development of a new concept of live recombinant vaccines (20 million yen a year) from Daiichi-Sankyo Pharmaceutical.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sawada, A., Yamaji, Y. & Nakayama, T. Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains. J Infect Chemother 19, 480–485 (2013). https://doi.org/10.1007/s10156-012-0515-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-012-0515-3